Levodopa and Decarboxylase Inhibitors: A Review of their Clinical Pharmacology and Use in the Treatment of Parkinsonism (original) (raw)

• Agnoli, A.; Cassacchia, M.; Fazio, C.; Ruggieri, S.; Zamponi, A.; Mancini, G.; Muratorio, A. and Pirro, R.: Comparison between the therapeutic effects of l-dopa and l-dopa plus dopa decarboxylase inhibitors in Parkinson’s disease. In Yahr, Current Concepts in the Treatment of Parkinsonism, p.87–94 (Raven Press, New York 1974).
  Google Scholar
• Andrews, C.J. and Somerville, B.: Levodopa combined with MK 486 (L-alpha methyldopahydrazine) —a peripheral decarboxylase inhibitor in Parkinson’s disease. Medical Journal of Australia 1: 429 (1974).
  CAS PubMed Google Scholar
• Ayd, F.J.: Treatment of depression with a peripheral decarboxylase inhibitor and levodopa. International Drug Therapy Newsletter 5: 35 (1970).
  Google Scholar
• Bakke, O.M. and Scheline, R.R.: Inhibition of a minor pathway of l-dopa metabolism in the intestinal lumen using a decarboxylase inhibitor (Ro 4-4602). Journal of Pharmacy and Pharmacology 26: 377 (1974).
  Article CAS PubMed Google Scholar
• Barbeau, A.: Treatment of Parkinson’s disease with l-dopa and Ro 4-4602: Review and present status. Advances in Neurology 2: 173 (1973).
  Google Scholar
• Barbeau, A.: The clinical physiology of side-effects in long-term l-dopa therapy. Advances in Neurology 5: 347 (1974).
  CAS PubMed Google Scholar
• Barbeau, A.: Long-term assessment of levodopa therapy in Parkinson’s disease. Canadian Medical Association Journal 112: 1379 (1975a).
  CAS PubMed Google Scholar
• Barbeau, A.: Potentiation of levodopa effect by intravenous L-prolyl-L-leucyl-glycine amide in man. Lancet 2: 683 (1975b).
  Article CAS PubMed Google Scholar
• Barbeau, A.; Mars, H. and Gillo-Joffroy, L.: Adverse clinical side-effects of levodopa therapy. In McDowell and Markham, Recent Advances in Parkinson’s Disease, p.204–237 (Davis, Philadelphia 1971).
  Google Scholar
• Bergmark, J.; Carlsson, A.; Granerus, A.K.; Jagenburg, R.; Magrusson, T. and Svanborg, A.: Decarboxylation of orally administered l-dopa in the human digestive tract. Naunyn-Schmiedebergs Archives of Pharmacology 272: 437 (1972).
  Article CAS Google Scholar
• Bianchine, J.R.; Messiha, F.S. and Hsu, T.H.: Peripheral aromatic L-amino acid decarboxylase inhibitor in Parkinsonism. II. Effect on metabolism of L-2-14 C-dopa. Clinical Pharmacology and Therapeutics 13: 584 (1972).
  CAS PubMed Google Scholar
• Birkmayer, W.: Twelve years’ experience with l-dopa treatment of Parkinson’s disease. In Yahr, Current Concepts in the Treatment of Parkinsonism, p.141–149 (Raven Press, New York 1974).
  Google Scholar
• Birkmayer, W.; Linauer, W.; Mentasti, M. and Riederer, P.: Zweijahrige Erfahrungen mit einer Kombinationsbehandlung des Parkinson-Syndroms mit l-Dopa und dem Dekarboxylasehemmer Benserazid (Ro 4-4602). Wiener Medizinische Wochenschrift 124: 340 (1974).
  CAS PubMed Google Scholar
• Birket-Smith, E.: Abnormal involuntary movements induced by anticholinergic therapy. Acta Neurologica Scandinavica 50: 801 (1974).
  Article CAS PubMed Google Scholar
• Boismare, F.; Belliard, J.-P. and Hacpille, L.: Effets de la l-dopa (associee ou non a un inhibiteur de la dopade-carboxylase extracerebrale) sur le debit vertebral et femoral du chien en decabitus et en orthostatisme. Journal de Pharmacologie 6: 15 (1975).
  CAS Google Scholar
• Boismare, F. and Boquet, J.: Levodopa and dopade-carboxylase/inhibitor in treatment of postural hypotension. British Medical Journal 1: 573 (1975).
  Article CAS PubMed Google Scholar
• Bonomi, L.M.: Experiencia con l-dopa asociada a bensera ida en sindromes parkinsonianos. La Prensa Medica Argentina 61: 972 (1974).
  Google Scholar
• Boudin, G.; Pepin, B.; Guillard, A.; Godlewski, S.; Fabiani, J.M. and Hagenau, M.: Resultats apres trois a cinq ans de traitement de 219 cas de syndrome parkinsonien traite par la l-dopa et l’association l-dopa inhibiteur de la decarboxylase. Revue Neurologique 130: 273 (1974).
  CAS PubMed Google Scholar
• Brogden, R.N.; Speight, T.M. and Avery, G.S.: Levodopa: A review of its pharmacological properties and therapeutic uses with particular reference to Parkinsonism. Drugs 2: 262 (1971).
  Article CAS PubMed Google Scholar
• Bronaugh, R.L.; Wenger, G.R.; Garver, D.L. and Rutledge, CO.: Metabolism of l-dopa in the pigtail monkey: Effect of a dopa decarboxylase inhibitor. Pharmacologist 16: 236 (1974).
  Google Scholar
• Calne, D.B.: Cardiovascular problems with l-dopa therapy. In Yahr, Current Concepts in the Treatment of Parkinsonism, p. 189–201 (Raven Press, New York 1974).
  Google Scholar
• Calne, D.B.; Brennan, J.; Spiers, A.S.D. and Stern, G.M.: Hypotension caused by l-dopa. British Medical Journal 1: 474 (1970).
  Article CAS PubMed Google Scholar
• Calne, D.B.; Petrie, A.; Rao, S.; Reid, J.L. and Vakil, S.D.: Action of L-α-methyldopahydrazine on the blood pressure of patients receiving levodopa. British Journal of Pharmacology 44: 162 (1972).
  Article CAS PubMed Google Scholar
• Calne, D.B.; Reid, J.L.; Vakil, S.D.; George, C.F. and Rao, S.: Effects of carbidopa and l-dopa on blood pressure in man. Advances in Neurology 2: 149 (1973).
  Google Scholar
• Calne, D.B.; Reid, J.L.; Vakil, S.D.; Rao, S.; Petrie, A.; Pallis, C.A.; Gawler, J.; Thomas, P.K. and Hilson, A.: Idiopathic Parkinsonism treated with an extracerebral decarboxylase inhibitor in combination with levodopa. British Medical Journal 3: 729 (1971).
  Article CAS PubMed Google Scholar
• Calne, D.B.; Teychenne, P.F.; Claveria, L.E.; Eastman, R.; Greenacre, J.K. and Petrie, A.: Bromocriptine in Parkinsonism. British Medical Journal 4: 442 (1974a).
  Article CAS PubMed Google Scholar
• Calne, D.B.; Teychenne, P.F.; Leigh, P.N.; Bamji, A.N. and Greenacre, J.K.: Treatment of Parkinsonism with bromocriptine. Lancet 2: 1355 (1974b).
  Article CAS PubMed Google Scholar
• Celesia, G.C. and Wanamake, W.: New combination therapy, carbidopa-L-dopa, in the treatment of Parkinson’s disease. Wisconsin Medical Journal 73: 5110 (1974).
  Google Scholar
• Chase, T.N. and Watanabe, A.M.: Methyldopahydrazine as an adjunct to l-dopa therapy in Parkinsonism. Neurology 22: 384 (1972).
  Article CAS PubMed Google Scholar
• Christiani, K. and Moller, W.D.: Die medikamentose Therapie des Parkinson-Syndroms. Eine klinische Langseitstudie mit l-Dopa und dem Kombination-spraparat L-Dopa—Decarboxylasehemmer. Münchener Medizinische Wochenschrift 115: 711 (1973).
  CAS PubMed Google Scholar
• Clark, W.G.; Oldendorf, W.H. and Dewhurst, W.G.: Blood-brain barrier to carbidopa (MK-486) and Ro 4-4602, peripheral dopa decarboxylase inhibitors. Journal of Pharmacy and Pharmacology 25: 416 (1973).
  Article CAS PubMed Google Scholar
• Constantinidis, J.; Siegfried, J. and Frigyesi, T.L.: Parkinson’s disease and striatal dopamine: In vivo morphological evidence for the presence of dopamine in the human brain. Journal of Neural Transmission 35: 13 (1974).
  Article CAS PubMed Google Scholar
• Constantinidis, J.; Bartholini, G.; Geissbuhler, F. and Tissot, R.: La barriere capillaire enzymatique pour la dopa au niveau de quelques noyaux du tronc cerebral du rat. Experientia 26: 381 (1969).
  Article Google Scholar
• Costall, B.; Naylor, R.J. and Pinder, R.M.: Design of agents for stimulation of neostriatal dopaminergic mechanisms. Journal of Pharmacy and Pharmacology 26: 753 (1974).
  Article CAS PubMed Google Scholar
• Cotzias, G.C. and Papavasiliou, P.S.: Blocking the negative effect of pyridoxine on patients receiving levodopa. Journal of the American Medical Association 215: 1504 (1971).
  Article CAS PubMed Google Scholar
• Cotzias, G.C.; Papavasiliou, P.S.; Düby, S.E.; Steck, A.J. and Ginos, J.Z.: Some newer metabolic concepts in the treatment of Parkinsonism. Neurology 22 (Suppl): 82 (1972).
  Article Google Scholar
• Cotzias, G.C.; Papavasiliou, P.S.; Tolosa, E.D.; Mendez, J.S. and Bell-Midura, M.: Treatment of Parkinson’s disease with aporphines. New England Journal of Medicine 294: 567 (1976).
  Article CAS PubMed Google Scholar
• Cotzias, G.C.; Van Woert, M.H. and Schiffer, L.M.: Aromatic amino acids and modification of Parkinsonism. New England Journal of Medicine 276: 374 (1967).
  Article CAS PubMed Google Scholar
• Damasio, A.R.; Castro-Caldas, A. and Levy, A.: The on-off effect. Advances in Neurology 3: 11 (1973).
  Google Scholar
• Dashmana, K.M. and Spilker, B.A.: On the mechanism of l-dopa induced postural hypotension in the cat. British Journal of Pharmacology 47: 437 (1973).
  Article Google Scholar
• De la Torre, J.C.: Localisation of dopamine in brain following administration of l-dopa and a decarboxylase inhibitor. Advances in Neurology 2: 59 (1973).
  Google Scholar
• Desjacques, P.; Moret, P. and Gauthier, G.: Effets cardiovasculaire de la l-dopa et de l’inhibiteur de la decarboxylase chez les malades atteints de la maladie de Parkinson. Schweizerische Medizinische Wochenschrift 103: 1783 (1973).
  CAS PubMed Google Scholar
• Dietrichson, P.; Presthur, J. and Holmsen, R.: Treatment of Parkinsonism with L-dopa and a decarboxylase inhibitor. An electrophysiological and clinical study. European Neurology 13: 339 (1975).
  CAS Google Scholar
• Dunner, D.L.; Brodie, K.H. and Goodwin, F.K.: Plasma dopa response to levodopa administration in man: Effects of a peripheral decarboxylase inhibitor. Clinical Pharmacology and Therapeutics 12: 212 (1971).
  CAS PubMed Google Scholar
• Duvoisin, R.C.: Pyridoxine as an adjunct in the treatment of Parkinsonism. Advances in Neurology 2: 229
• Duvoisin, R.C.: Hyperkinetic reactions with l-dopa. In Yahr, Current Concepts in the Treatment of Parkinsonism, p.203–210 (Raven Press, New York 1974).
  Google Scholar
• Duvoisin, R.C.: Antagonism of levodopa by papaverine. Journal of the American Medical Association 231: 845 (1975).
  Article CAS PubMed Google Scholar
• Editorial: Miracle cures in Parkinson’s disease. British Medical Journal 3: 1 (1975).
• Eisenring, J.J.; Dick, P.; Tissot, R. and Yanniotis, G.: Association L-dopa desipramine et inhibiteur de la decarboxylase dans le traitement de la depression. Psychopharmacologia 33: 95 (1973).
  Article CAS PubMed Google Scholar
• Fahn, S.: ‘On-off’ phenomenon with levodopa therapy in parkinsonism. Clinical and pharmacologic correlations and the effect of intramuscular pyridoxine. Neurology 24: 431 (1974).
  CAS Google Scholar
• Fazio, C.; Agnoli, A.; Casacchia, M.; Reitano, M.; Ruggieri, S.; Barba, C. and Volante, F.: Treatment of Parkinson’s disease with l-dopa and an association l-dopa plus a dopa decarboxylase inhibitor. Zeitschrift fur Neurologie 202: 347 (1972).
  Article CAS PubMed Google Scholar
• Ferel, D.: Die Behandlung des Parkinson-Syndroms mit l-dopa und einem Dekarboxylasehemmer (Ro 4-4602). Schweizerische Medizinische Wochenschrift 102: 88 (1972).
  CAS PubMed Google Scholar
• Foltz, E.L.; Feinberg, J.A.; Breault, G.O.; Jaffe, M.E. and Bear, J.E.: Augmentation of available dopa after oral administration of l-dopa with a decarboxylase inhibitor, levo-3-(3,4-dihydroxyphenyl)-2-hydrazino-2-methylpropionic acid monohydrate (HMD). International Journal of Clinical Pharmacology, Therapy, and Toxicology 6: 95 (1972).
  Google Scholar
• Gattringer, B. and Steinhausl, H.: Vorteile der Kombinationsbehandlung (L-Dopa und Dekarboxylasehemmer) des Parkinsonsyndroms. Wiener Medizinische Wochenschrift 122: 369 (1972).
  CAS PubMed Google Scholar
• Gauthier, G.; Juge, O. and Birchler, A.: Parkinsonian syndromes. Treatment by association of l-dopa plus decarboxylase inhibitor. European Neurology 11: 133 (1974).
  CAS Google Scholar
• Glasgow, G.L.; Henly, J.W. and Willoughby, E.W.: L-Alpha-methyldopa hydrazine (Carbidopa) combined with l-dopa in the treatment of Parkinson’s disease. Australian and New Zealand Journal of Medicine 4: 373 (1974).
  Article CAS PubMed Google Scholar
• Goldberg, LI. and Whitsett, T.L. Cardiovascular effects o levodopa. Qinical Pharmacology and Therapeutics 12: 376 (1971).
  CAS Google Scholar
• Gorlich, J. and Markus, E.: L-dopa-Therapie des Parkinson-Syndroms. Vergleich von reinem l-Dopa und dem Kombinationspraparat l-Dopa + Decarboxylasehemmer. Deutsche Medizinische Wochenschrift 97: 1246 (1972).
  Article CAS PubMed Google Scholar
• Goodwin, F.K.; Murphy, D.L.; Brodie, K.H. and Bunney, W.E.: Levodopa: Alterations in behaviour. Qinical Pharmacology and Therapeutics 12: 383 (1971).
  CAS Google Scholar
• Insausti, T. and Ferreiro, J.: L-Dopa asociado a un inhibidor de la decarboxilasa periferica en sindromes parkinsonienos. La Prensa Medica Argentina 60: 170 (1973).
  Google Scholar
• Jaffe, M.E.: Qinical studies of carbidopa and l-dopa in the treatment of Parkinson’s disease. Advances in Neurology 2: 161 (1973).
  Google Scholar
• Keenan, R.E.: The Eaton collaborative study of levodopa therapy in parkinsonism: a summary. Neurology 20 (Suppl.): 46 (1970).
  Article CAS Google Scholar
• Klaiber, R.; Siegfried, J.; Ziegler, W.H. and Perret, E.: Psychomotor effects of l-dopa combined with a decarboxylase inhibitor on Parkinsonian patients. European Journal of Clinical Pharmacology 3: 172 (1971).
  Article Google Scholar
• Klawans, H.L.; Ringel, S.P. and Shenker, D.M.: Failure of vitamin B6 to reverse the l-dopa effect in patients on a dopa decarboxylase inhibitor. Journal of Neurology, Neurosurgery, and Psychiatry 34: 682 (1971).
  Article CAS PubMed Google Scholar
• Knuttson, E. and Martensson, A.: Improvement in mono-manual dexterity in Parkinsonism when supplementing levodopa with an extracerebral decarboxylase inhibitor, Ro 4-4602. Scandinavian Journal of Rehabilitation Medicine 6: 89 (1974).
  Google Scholar
• Kopin, I.J.: Modification by inhibition of decarboxylase of the cardiovascular effects of l-dopa in animals. Advances in Neurology 2: 137 (1973).
  CAS Google Scholar
• Korten, J.J.; Keyser, A.; Joosten, E.M.G. and Gabreels, F.J.M.: Madopar versus Sinemet. A clinical study of their effectiveness. European Neurology 13: 65 (1975).
  CAS Google Scholar
• Kremzner, L.T.; Berl, S.; Mendoza, M. and Yahr, M.D.: Cerebrospinal fluid levels of dopa and 3-0-methyldopa in Parkinsonism during treatment with l-dopa and MK-486. Advances in Neurology 2: 79 (1973).
  Google Scholar
• Kuruma, I.; Bartholini, G.; Tissot, R. and Pletscher, A.: Comparative investigation of inhibitors of extracerebral dopa decarboxylase in man and rats. Journal of Pharmacy and Pharmacology 24: 289 (1972).
  Article CAS PubMed Google Scholar
• Leibowitz, M. and Iieberman, A.: Comparison of dopa decarboxylase inhibitor (carbidopa) combined with levodopa and levodopa alone on the cardiovascular system of patients with Parkinson’s disease. Neurology 25: 917 (1975).
  Article CAS PubMed Google Scholar
• Lieberman, A.N.; Derby, B.M.; Feigenson, J.; Goodgold, A.; Nesbitte, J.; Resurreccion, E.C. and Valdivia, F.: MK 486 and levodopa in the treatment of Parkinsonism. Diseases of the Nervous System 34: 167 (1973a).
  Google Scholar
• Lieberman, A.; Goodgold, A.; Jonas, S.; Leibowitz, M.; Rosenblum, J. and Tarlau, M.: Comparative effectiveness of MK-486 (Carbidopa) and levodopa in Parkinson’s disease. Neurology 23: 439 (1973b).
  Google Scholar
• Lieberman, A.; Goodgold, A.; Jonas, S. and Leibowitz, M.: Comparison of dopa decarboxylase inhibitor (carbidopa) combined with levodopa and levodopa alone in Parkinson’s disease. Neurology 25: 911 (1975a).
  Article CAS PubMed Google Scholar
• Lieberman, A.; Mijamoto, T.; Battista, A.F. and Goldstein, M.: Studies on the antiparkinsonian efficacy of lergotrile. Neurology 25: 459 (1975b).
  Article CAS PubMed Google Scholar
• Lieberman, A.N. and Shupack, J.L.: Levodopa and melanoma. Neurology 24: 340 (1974).
  Article CAS PubMed Google Scholar
• Lotti, V.J.: Experimental pharmacology of carbidopa (MK-486) and l-dopa: animal studies. Advances in Neurology 2: 91 (1973).
  CAS Google Scholar
• Lotti, V.J. and Clark, C.: Carbidopa attenuation of L-dopa emesis in dogs: evidence for a cerebral site of action outside the blood-brain barrier. European Journal of Pharmacology 25: 322 (1974).
  Article CAS PubMed Google Scholar
• Lotti, V.J. and Porter, C.C.: Potentiation and inhibition of some central actions of L(−)-dopa by decarboxylase inhibitors. Journal of Pharmacology and Experimental Therapeutics 172: 406 (1970).
  CAS PubMed Google Scholar
• Markham, C.H.; Diamond, G.H. and Treciokas, L.J.: Carbidopa in Parkinson’s disease and in nausea and vomiting of levodopa. Archives of Neurology 31: 128 (1974).
  Article CAS PubMed Google Scholar
• Mars, H.: Modification of dopa effect by decarboxylase inhibition. Neurology 22: 417 (1974).
  Google Scholar
• Mars, H.: Modification of levodopa effect by systemic decarboxylase inhibition. Archives of Neurology 28: 91 (1973a).
  Article CAS PubMed Google Scholar
• Mars, H.: Metabolic interaction of pyridoxine, levodopa, and carbidopa in Parkinson’s disease. Transactions of the American Neurological Association 98: 241 (1973b).
  CAS PubMed Google Scholar
• Mars, H.: Levodopa, carbidopa, and pyridoxine in Parkinson’s disease. Archives of Neurology 30: 444 (1974).
  Article CAS PubMed Google Scholar
• Mars, H.; Barera, E.R. and Bennett, S.: Levodopa and pyridoxine. Journal of the American Medical Association 219: 1764 (1972).
  Article CAS PubMed Google Scholar
• Mars, H. and Genuth, S.M.: Potentiation of levodopa stimulation of human growth hormone by systemic decarboxylase inhibition. Clinical Pharmacology and Therapeutics 14: 390 (1973).
  CAS PubMed Google Scholar
• Marsden, C.D.: Combined treatment with selective decarboxylase inhibitors; in Stern, The Clinical Uses of Levodopa, p.107 (MTP, London 1975).
  Google Scholar
• Marsden, C.D.; Barry, P.E.; Parkes, J.D. and Zilkha, K.J.: Treatment of Parkinson’s disease with levodopa combined with L-alpha-methyldopahydrazine, an inhibitor of extracerebral dopa decarboxylase. Journal of Neurology, Neurosurgery and Psychiatry 36: 10 (1973c).
  Article CAS Google Scholar
• Marsden, C.D. and Parkes, J.D.: ‘On-off’ effects in patients with Parkinson’s disease on chronic levodopa therapy. Lancet 1: 292 (1976).
  Article CAS PubMed Google Scholar
• Marsden, C.D.; Parkes, J.D. and Rees, J.E.: Long-term treatment of Parkinson’s disease with an extracerebral dopa decarboxylase inhibitor (L-alphamethyldopahydrazine, MK 486) and levodopa. Advances in Neurology 3: 79 (1973a).
  Google Scholar
• Marsden, C.D.; Parkes, J.D. and Rees, J.E.: A year’s comparison of treatment of patients with Parkinson’s disease with levodopa combined with carbidopa versus treatment with levodopa alone. Lancet 2: 1459 (1973b).
  Article CAS PubMed Google Scholar
• Marsden, C.D.; Parkes, J.D. and Rees, J.E.: A comparison of treatment of Parkinson’s disease with l-dopa and with Sinemet. In Yahr, Current Concepts in the Treatment of Parkinsonism, p.21–36 (Raven Press, New York 1974).
  Google Scholar
• Martinez-Lage, J.M.; Marti-Masso, J.F.; Carrera, N. and Del Arno, F.: Un ano de tratamiento con carbidopa y levodopa en enfermos parkinsonianos. Revista Clinica Espanola 134: 535 (1974a).
  CAS PubMed Google Scholar
• Martinez-Lage, J.M.; Marti-Masso, J.F.; Carrera, N. and Maravi, E.: A single blind comparative study with the combination of carbidopa and l-dopa in Parkinson’s disease treatment. In Yahr, Current Concepts in the Treatment of Parkinsonism. p.1–19 (Raven Press, New York 1974b).
  Google Scholar
• Mendez, J.S.; Cotzias, G.C.; Papavasiliou, P.S. and Mena, I.: ‘On-off’ phenomenon during treatment of Parkinsonism with l-dopa. In Yahr, Current Concepts in the Treatment of Parkinsonism, p.151–160 (Raven Press, New York 1974).
  Google Scholar
• Miller, E.M. and Wiener, L.: Ro 4-4602 and levodopa in the treatment of parkinsonism. Neurology 24: 482 (1974).
  Article CAS PubMed Google Scholar
• Mones, R.J.: Evaluation of alphamethyl dopa and alpha methyl dopa hydrazine with l-dopa therapy. New York State Journal of Medicine 1: 47 (1974).
  Google Scholar
• Nevalainen, T.; Reikkinen, P.; Rinne, V.K. and Sonninen; V.: Morphological and biochemical studies on liver biopsies of Parkinsonian patients treated with levodopa and decarboxylase inhibitors. Acta Neurologica Scandinavica 50: 122 (1974).
  Article CAS PubMed Google Scholar
• Ohmoto, T. and Kishikawa, H.: L-Dopa therapy combined with peripheral decarboxylase inhibitor (MK-486) in Parkinsonism. Folia Psychiatrica et Neurologica Japonica 29: 1 (1975).
  CAS PubMed Google Scholar
• Olanow, C.W. and Schwartz, A.M.: A controlled blind double-observer study of MK-486 (carbidopa) in Parkinson’s disease. In Yahr, Current Concepts in the Treatment of Parkinsonian, p.69–86 (Raven Press, New York 1974).
  Google Scholar
• Papavasiliou, P.S.; Cotzias, G.C.; Düby, S.E.; Steck, A.J.; Bell, M. and Lawrence, W.H.: Melatonin and Parkinsonism. Journal of the American Medical Association 221: 88 (1972b).
  Article CAS PubMed Google Scholar
• Papavasiliou, P.S.; Cotzias, G.C.; Düby, S.E.; Steck, A.J.; Fehling, C. and Bell, M.A.: Levodopa in Parkinsonism: Potentiation of central effects with a peripheral inhibitor. New England Journal of Medicine 286: 8 (1972a).
  Article CAS PubMed Google Scholar
• Papavasiliou, P.S.; Cotzias, G.C. and Lawrence, W.H.: Levodopa and dopamine in cerebrospinal fluid. Neurology 23: 756 (1973).
  Article CAS PubMed Google Scholar
• Parks, L.C.; Watanabe, A.M. and Kopin, I.J.: Prevention or reversal of levodopa-induced cardiac arrhythmias by decarboxylase inhibitors. Lancet 2: 1014 (1970).
  Article CAS PubMed Google Scholar
• Parkes, J.D.; Tarsy, D.; Marsden, C.D.; Bovell, K.; Phipps, J.A.; Rose, P. and Asselman, P.: Amphetamines in the treatment of Parkinson’s Disease. Journal of Neurology, Neurosurgery and Psychiatry 38: 232 (1975).
  Article CAS Google Scholar
• Paty, D.W.; Jaatoul, N.; Kertesz, A. and McInnis, W.: Alpha-methyldopahydrazine as an adjunct to levodopa therapy in Parkinson’s disease. Canadian Journal of Neurological Sciences 2: 169 (1975).
  CAS PubMed Google Scholar
• Pinder, R.M.: The pharmacotherapy of Parkinsonism. Progress in Medicinal Chemistry 9: 191 (1972).
  Article Google Scholar
• Pinder, R.M.: Design of dopamine-like drugs. Advances in Neurology 3: 295 (1973).
  CAS Google Scholar
• Pinder, R.M.: Structural requirements for central dopamine-like activity; in Medicinal Chemistry IV. Proceedings of the 4th International Medicinal Chemistry Symposium, Nijmegen, 1974 (Elsevier, Amsterdam 1975).
• Pletscher, A.: Effect of inhibitors of extracerebral decarboxylase on levodopa metabolism. Advances in Neurology 3: 49 (1973).
  CAS Google Scholar
• Pletscher, A. and Bartholini, G.: Selective rise in brain dopamine by inhibition of extracerebral levodopa decarboxylation. Clinical Pharmacology and Therapeutics 12: 344 (1971).
  CAS PubMed Google Scholar
• Porter, C.C.: Inhibitors of aromatic amino acid decarboxylase —their biochemistry. Advances in Neurology 2: 37 (1973).
  CAS Google Scholar
• Preziosi, T.J.; Bianchine, J.R.; Hsu, T.H. and Messiha, F.S.: L-Methyldopa hydrazine (MK 486) and l-dopa; A double-blind study in Parkinsonism. Transactions of the American Neurological Association 97: 321 (1972).
  Google Scholar
• Reid, J.L.; Calne, D.B.; Vakil, S.D.; Allan, J.G. and Davies, C.A.: Plasma concentration of levodopa in Parkinsonism before and after inhibition of peripheral decarboxylase. Journal of the Neurological Sciences 17: 45 (1972a).
  Article CAS PubMed Google Scholar
• Reid, J.L.; Calne, D.B.; George, CF. and Vakil, S.D.: Levodopa and pressor amine sensitivity in parkinsonism. Clinical Pharmacology and Therapeutics 13: 400 (1972b).
  CAS PubMed Google Scholar
• Rinne, U.K. and Sonninen, V.: Brain catecholamines and their metabolites in Parkinsonian patients. Archives of Neurology 28: 107 (1973).
  Article CAS PubMed Google Scholar
• Rinne, U.K.; Sonninen, V. and Siirtola, T.: Treatment of Parkinson’s disease with l-dopa and decarboxylase inhibitor. Zeitschrift fur Neurologie 202: 1 (1972).
  Article CAS PubMed Google Scholar
• Rinne, U.K.; Sonninen, V. and Siirtola, T.: Plasma concentration of levodopa in patients with Parkinson’s disease. Response to levodopa alone or combined with a decarboxylase inhibitor and clinical correlations. European Neurology 10: 301 (1973a).
  CAS Google Scholar
• Rinne, U.K.; Sonninen, V. and Siirtola, T.: Acid monoamine metabolites in the cerebrospinal fluid of Parkinsonian patients treated with levodopa alone or combined with a decarboxylase inhibitor. European Neurology 9: 349 (1973b).
  Article CAS PubMed Google Scholar
• Rinne, U.K.; Sonninen, V. and Siirtola, T.: Treatment of Parkinsonian patients with levodopa and extracerebral decarboxylase inhibitor, Ro 4-4602. Advances in Neurology 3: 59 (1973c).
  Google Scholar
• Rondot, P. and Ribadeau Dumas, J.L.: Treatment of Parkinson’s disease with a decarboxylase inhibitor. In Yahr, Current Concepts in the Treatment of Parkinsonism, p.61–68 (Raven Press, New York 1974).
  Google Scholar
• Sandier, M.; Johnson, R.D.; Ruthven, C.R.J.; Reid, J.L. and Calne, D.B.: Transamination is a major pathway of l-dopa metabolism following peripheral decarboxylase inhibition. Nature 247: 364 (1974).
  Article Google Scholar
• Savino, A.A.; Matera, R.V. and Matera, R.F.: Tratamiento del parkinsanismo en pacients que no respondieron a la l-dopa. Prensa Medica Argentina 61: 353 (1974).
  Google Scholar
• Schneider, E.; Fischer, P.A.; Jacobi, P. and Maxion, H.: Wirkungsvergleich von l-dopa und der Kombination l-Dopa + Decarboxylasehemmer beirn Parkinson-Syndrom. Archiv fur Psychiatrie und Nervenkrankheiten 217: 95 (1973).
  Article CAS PubMed Google Scholar
• Schwartz, A.M.; Olanow, C.W. and Spencer, A.: A double-blind controlled study of MK-486 in Parkinson’s disease. Transactions of American Neurological Association 98: 301 (1973).
  CAS Google Scholar
• Schwartz, D.E.; Jordan, J.C. and Ziegler, W.H.: Pharmacokinetics of the decarboxylase inhibitor benserazide in man; its tissue distribution in the rat. European Journal of Clinical Pharmacology 7: 39 (1974).
  Article CAS PubMed Google Scholar
• Shaw, K.M.; Stern, G.M. and Sandler, M.: Melatonin and metatyrosine in the treatment of Parkinsonism. Advances in Neurology 3: 115 (1973).
  Google Scholar
• Stammler, A. and Vielhaber, K.: Die Behandlung des Parkinsonsyndroms mit l-Dopa in Kombination mit einem Decarboxylasehemmer. Fortschritte Neurologie und Psychiatrie 40: 564 (1972).
  CAS Google Scholar
• Steinhausl, H.: Erfahrungsbericht uber die Behandlung des Parkinson-Syndroms mit dem Kombinationspraparat l-Dopa + Dekarboxylasehemmer (Ro 8-0576). Wiener Medizinische Wochenschrift 123: 433 (1973).
  CAS PubMed Google Scholar
• Sweet, R.D.; McDowell, F.H.; Wasterlain, C.G. and Stern, P.H.: Treatment of ‘on-off’ effect with a dopa decarboxylase inhibitor. Archives of Neurology 32: 560 (1975).
  Article CAS PubMed Google Scholar
• Sweet, R.D.; Wasterlain, C.G. and McDowell, F.H.: The effect of a peripheral dopa decarboxylase inhibitor on irregularities of response to l-dopa (‘on-off’ effect). Neurology 23: 445 (1973).
  Google Scholar
• Theiss, E. and Scharer, K.: Toxicity of l-dopa and a decarboxylase inhibitor in animal experiments. In De Ajuriaguerra and Gauthier, Monoamines Noyaux Grix Centraux et Syndrome de Parkinson, p.497 (Georg & Cie, Geneva 1971).
  Google Scholar
• Tissot, R.; Bartholini, G. and Retscher, A.: Drug-induced changes of extracerebral dopa metabolism in man. Archives of Neurology 20: 187 (1969).
  Article CAS PubMed Google Scholar
• Tissot, R. and De Ajuriaguerra, J.: Syndrome de Parkinson. Quatre ans d’experience de la therapeutique par la l-dopa associee a un inhibiteur de la decarboxylase. Etude clinique et biochimique. La Nouvelle Presse Medicale 2: 315 (1973).
  CAS PubMed Google Scholar
• Tissot, R.; Eisenring, J.J. and Constantinidis, J.: Modes of action and optimal dosage of decarboxylase inhibitors. In Yahr, Current Concepts in the Treatment of Parkinsonism. p. 123–132 (Raven Press, New York 1974).
  Google Scholar
• Tolosa, E.S.; Martin, W.E.; Cohen, H.P. and Jacobson, R.L.: Patterns of clinical response and plasma dopa levels in Parkinson’s disease. Neurology 25: 177 (1975).
  Article CAS PubMed Google Scholar
• Vakil, S.D.; Calne, D.B.; Reid, J.L. and Seymour, CA.: Pyrinidyl—Piperanyl—Piperazine (ET 495) in Parkinsonism. Advances in Neurology 3: 121 (1973).
  Google Scholar
• Van Wieringen, A.: Benserazid with l-dopa in the treatment of Parkinson’s disease. South African Medical Journal 48: 206 (1974).
  PubMed Google Scholar
• Vesell, E.S.; Ng, L.; Passananti, G.T. and Chase, T.N.: Inhibition of drug metabolism by levodopa in combination with dopa-decarboxylase inhibitor. Lancet 2: 370 (1971).
  Article CAS PubMed Google Scholar
• Vesell, E.S.; Passananti, G.T. and Greene, F.E.: Impairment of drug metabolism in man by allopurinol and amitriptyline. New England Journal of Medicine 383: 1484 (1970).
  Article Google Scholar
• Vicary, D.J.; Horrocks, P.M.; Rees, J.E.; Parkes, J.D. and Marsden, C.D.: The treatment of patients with Parkinson’s disease receiving levodopa. Clinical Trials Journal 10: 3 (1973).
  Google Scholar
• Vickers, S.; Stuart, E.K.; Bianchine, J.R.; Hucker, H.B.; Jaffe, M.E.; Rhodes, R.E. and Vandenheuvel, W.J.A.: Metabolism of carbidopa [L-(−)-α-hydrazino-3,4-dihydroxy-α-methylhydrocinnamic acid monohydrate], an aromatic amino acid decarboxylase inhibitor, in the rat, dog, rhesus monkey and man. Drug Metabolism and Disposition 2: 9 (1974).
  CAS PubMed Google Scholar
• Vickers, S.; Stuart, E.K.; Hucker, H.B. and Vandenheuvel, W.J.A.: Further studies on the metabolism of carbidopa, (−)-L-α-hydrazino-3,4-dihydroxy-β-methyl-benzenepropanoic acid monohydrate, in the human, rhesus monkey, dog, and rat. Journal of Medicinal Chemistry 18: 134 (1975).
  Article CAS PubMed Google Scholar
• Vogel, W.H.; Mahoney, K. and Hare, T.A.: Inhibition of dopa decarboxylation by Ro 4-4602, MK 485, and MK 486 in human liver homogenates. Archives Internationales de Pharmacodynamie et de Therapie 198: 85 (1972).
  CAS PubMed Google Scholar
• Voller, G.W. and Muschard, F.: Zur Therapie des Parkinson-Syndroms mit einer Kombination zwischen l-Dopa und einem Decarboxylasehemmer. Medizinische Welt 24: 705 (1973).
  CAS PubMed Google Scholar
• Walzholz, V. and Schonfelder, H.: Fortschritte in der Behandlung des Parkinson-Syndroms mit l-dopa durch Kombination mit einem Decarboxylasehemmer. Ergebrisse einer Langzeitstudie. Nervenartz 43: 531 (1972).
  CAS Google Scholar
• Wajsbort, J.; Hemli, J.A.; Alfandary, I.; Yahel, M. and Siegfried, J.: Klinische Blobachtungen uber die Kombinationsbehandlung des Parkinson-Syndroms mit l-dopa und dem Decarboxylasehemmer Ro 4-4602. Wiener Medizinische Wochenschrift 122: 741 (1971).
  Google Scholar
• Watanabe, A.M.; Chase, T.N. and Cardon, P.V.: Effect of l-dopa alone and in combination with an extracerebral decarboxylase inhibitor on blood pressure and some cardiovascular reflexes. Clinical Pharmacology and Therapeutics 11: 740 (1970).
  CAS PubMed Google Scholar
• Woods, A.C. and Chase, T.N.: M.I.F.: Effect on levodopa dyskinesias in man. Lancet 2: 513 (1973).
  Article CAS PubMed Google Scholar
• Yahr, M.D. and Duvoisin, R.C.: Pyridoxine and levodopa in the treatment of Parkinsonism. Journal of the American Medical Association 220: 861 (1975).
  Article Google Scholar
• Yahr, M.D.; Duvoisin, R.C.; Mendoza, M.R.; Schear, M.J. and Barrett, R.E.: Modification of l-dopa therapy of Parkinsonism by alpha-methyldopa hydrazine (MK-486). Transactions of the American Neurological Association 96: 55 (1972).
  Google Scholar
• Zwickey, R.E.; Peck, H.M.; Bagdon, W.J.; Bokelman, D.L.; Brown, W.R.; Hite, M.; Jensen, R.D.; Mattis, P.A.; Mendlowski, B.; Porter, C.C.; Tate, C.L. and Stone, C.A.: Preclinical toxicological studies of carbidopa and combinations of carbidopa and levodopa. Toxicology and Applied Pharmacology 29: 181 (1974).
  Article CAS PubMed Google Scholar